Consensus Novavax, Inc.

Stocks

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 19/09/2026 +04			5-day change	1st Jan Change
10.11 ^USD	+1.10%		+7.32%	+50.45%

09-10	Novavax, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10:00 AM
09-10	Novavax, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 09:45 AM

Evolution of the Average Target: Novavax, Inc.

Evolution of the Target Price: Novavax, Inc.

Changes in Analyst Recommendations: Novavax, Inc.

231.YpbJkaSEBIBuxfRGZWODArGZ6TuwwrHxPFGS5pQM65k.A-Oao8qwQM0hgp0HUxTtZ-jbvU_Gl9LBaz7f0dtPo_Yx4IzpksJg5A30rQ~b00520670a5152783e326032fe3a18d2

Analysts' recommendations: Novavax, Inc.

04-09	B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating	MT
11-11	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
11-10	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
20/08/25	Novavax: BofA downgrades stock
20/08/25	Novavax Faces 'Increasingly Murky' Outlook on Vaccine Uncertainties, BofA Securities Says	MT
20/08/25	BofA Downgrades Novavax to Underperform From Neutral, Adjusts Price Target to $7 From $9	MT
20/08/25	BofA Securities Downgrades Novavax to Underperform From Neutral, Price Target is $7	MT
05/05/25	B. Riley Cuts Price Target on Novavax to $18 From $22, Keeps Buy Rating	MT
28/02/25	BTIG Initiates Novavax at Buy With $19 Price Target	MT
18/11/24	B. Riley Adjusts Novavax Price Target to $22 From $26, Maintains Buy Rating	MT
16/10/24	Jefferies Cuts Novavax's Price Target to $25 From $31, Buy Rating Maintained	MT
10/10/24	B. Riley Raises Price Target on Novavax to $26 From $23, Keeps Buy Rating	MT
12/08/24	B. Riley Adjusts Price Target on Novavax to $23 From $25, Maintains Buy Rating	MT
02/08/24	B. Riley Adjusts Price Target on Novavax to $25 From $29, Maintain Buy Rating	MT
30/07/24	Novavax Shares Sink After JPMorgan Downgrades Rating to Underweight From Neutral	MT
30/07/24	JPMorgan Downgrades Novavax to Underweight From Neutral, Adjusts Price Target to $8	MT
23/05/24	B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	MT
01/03/24	HC Wainwright Cuts Price Target on Novavax to $19 From $35, Keeps Buy Rating	MT
23/02/24	B. Riley Trims Novavax's PT to $11 From $12 After Reaching Settlement on Gavi Arbitration Dispute, Keeps Buy Rating	MT
14/12/23	Novavax: green light for updated Covid vaccine in Sweden
10/11/23	B. Riley Lowers Novavax's Price Target to $12 From $15 After Near-Term COVID-19 Sales Estimate Revisions, Maintains Buy Rating	MT
09/08/23	B. Riley Upgrades Novavax to Buy From Neutral After Above-Consensus Q2 Beat, Says Turnaround Progressing; Retains $15 PT	MT
10/05/23	B. Riley Raises Novavax's PT to $15 From $10, Says Q1 Financial Update 'Not As Bad As Feared'; Keeps Neutral Rating	MT
01/03/23	B. Riley Downgrades Novavax to Neutral From Buy, Lowers Price Target to $10 From $29	MT
17/02/23	B. Riley Cuts Novavax's Price Target to $29 From $37, Maintains Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NOVAVAX, INC.					+40.02%
	LONZA GROUP AG					+26.27%
	IQVIA HOLDINGS INC.					+3.16%
	REVOLUTION MEDICINES, INC.					+27.56%
	BEONE MEDICINES AG					+22.45%
	CELLTRION, INC.					+49.02%
	MEDPACE HOLDINGS, INC.					-5.42%
	ASCENDIS PHARMA A/S					+30.8%
	EUROFINS SCIENTIFIC SE					-6.03%
	ICON PUBLIC LIMITED COMPANY					+9.18%
	Average					+19.70%
	Weighted average by Cap.					+20.19%